8-K - Mereo BioPharma Group plc (0001719714) (Filer)
Published . Updated .
Key takeaways
- 8-K - Mereo BioPharma Group filed an 8-K with the SEC on Nov 9 (a notice of a material company event).
- Exposed: MREO
- Market reaction: MREO +4.1% on the day
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Mereo BioPharma Group filed an 8-K with the SEC on Nov 9 (a notice of a material company event).
Directly affected
- MREO Mereo BioPharma Group
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Mereo BioPharma Group belongs to, so it often moves with news about it.
- NVS Novartis AG-0.4% 11d
Novartis AG is a peer of Mereo BioPharma Group in pharmaceutical preparations; rivals often move on the same news.
- AZN AstraZeneca+14.8% 30d
AstraZeneca is a peer of Mereo BioPharma Group in pharmaceutical preparations; rivals often move on the same news.
- NVO Novo Nordisk A/S-1.9% 30d
Novo Nordisk A/S is a peer of Mereo BioPharma Group in pharmaceutical preparations; rivals often move on the same news.
- GSK Gsk+0.7% 5d
Gsk is a peer of Mereo BioPharma Group in pharmaceutical preparations; rivals often move on the same news.
- SNY Sanofi
Sanofi is a peer of Mereo BioPharma Group in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| MREO | -0.18% | +7.25% | base | +4.10% | after close | after close | after close |
| XLV | -0.10% | +2.63% | base | +1.94% | after close | after close | after close |
| NVS | -0.72% | +1.46% | base | +0.64% | after close | after close | after close |
| AZN | +0.09% | +1.38% | base | +1.57% | after close | after close | after close |
| NVO | +0.38% | +4.64% | base | +2.70% | after close | after close | after close |
| GSK | -2.36% | +1.65% | base | +2.43% | after close | after close | after close |
| SNY | -3.15% | +0.91% | base | +2.35% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-09 AccNo: 0001193125-26-452716 Size: 538 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Mereo BioPharma Group (MREO) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| AZN | that day | +1.57% | final price |
| AZN | three days earlier | +1.38% | final price |
| AZN | five days earlier | +0.09% | final price |
| GSK | that day | +2.43% | final price |
| GSK | three days earlier | +1.65% | final price |
| GSK | five days earlier | -2.36% | final price |
| Mereo BioPharma Group (MREO) | that day | +4.10% | final price |
| Mereo BioPharma Group (MREO) | three days earlier | +7.25% | final price |
| Mereo BioPharma Group (MREO) | five days earlier | -0.18% | final price |
| NVO | that day | +2.70% | final price |
| NVO | three days earlier | +4.64% | final price |
| NVO | five days earlier | +0.38% | final price |
| NVS | that day | +0.64% | final price |
| NVS | three days earlier | +1.46% | final price |
| NVS | five days earlier | -0.72% | final price |
| SNY | that day | +2.35% | final price |
| SNY | three days earlier | +0.91% | final price |
| SNY | five days earlier | -3.15% | final price |
| XLV | that day | +1.94% | final price |
| XLV | three days earlier | +2.63% | final price |
| XLV | five days earlier | -0.10% | final price |
Congressional trades in the stocks in this story
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 74 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 10 Sep 2026. That is 60 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 31 Aug 2026. That is 70 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Scott Scott Franklin bought Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 26 Aug 2026. That is 75 days before publication. Filed 17 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Mereo BioPharma Group (MREO)
Companies mentioned with this story
- MREO Mereo BioPharma Group
In “8-K - Mereo BioPharma Group plc (0001719714) (Filer),” Mereo BioPharma Group (MREO) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> MREO
How “8-K - Mereo BioPharma Group plc (0001719714) (Filer)” reaches Mereo BioPharma Group (MREO)
“8-K - Mereo BioPharma Group plc (0001719714) (Filer)” (9 Nov 2026) reaches Mereo BioPharma Group (MREO) through this story.
For Mereo BioPharma Group (MREO), the reason on file says SEC 8-K filing -> direct issuer disclosure -> MREO
A simple score for Mereo BioPharma Group (MREO)
14 out of 100
“8-K - Mereo BioPharma Group plc (0001719714) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.